Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.67 USD

3.67
241,458

-0.14 (-3.67%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $3.74 +0.07 (1.91%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (64 out of 251)

Industry: Internet - Commerce

Better trading starts here.

Zacks News

Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius

Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.

    Hologic's FDA Nod for Quantra Software Boosts Breast Health

    Hologic (HOLX) is consistently trying to boost its Breast Health segment.

      Alibaba (BABA) Announces Proposed Offering of Senior Notes (Revised)

      Alibaba Group Holding Limited (BABA) announces plans of offering senior unsecured notes. The move will help the company bring down its cost of capital, thereby strengthening its balance sheet.

        The Zacks Analyst Blog Highlights: EVINE Live, ASOS, PetMed Express, Groupon, Amazon and Adobe Systems

        The Zacks Analyst Blog Highlights: EVINE Live, ASOS, PetMed Express, Groupon, Amazon and Adobe Systems

          Add These 4 Promising Stocks to Your Cyber Monday Cart

          Cyber Monday is expected to be the largest online shopping fiesta of all times, courtesy upbeat job data and record low unemployment rate.

            Here's Why You Should Add Amedisys (AMED) to Your Portfolio

            Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

              Here's Why You Should Invest in Masimo (MASI) Right Now

              Masimo (MASI) continues to grow on innovation and product launches.

                Luminex (LMNX) at 52-Week High: What's Driving the Stock?

                Luminex (LMNX) gains from recent FDA approvals and product launches.

                  Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain

                  Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.

                    Here's Why You Should Invest in Align Technology (ALGN) Now

                    Align Technology (ALGN) continues to boost investors' confidence on consistent strength in InvisAlign.

                      PetMed (PETS) Down 7.8% Since Earnings Report: Can It Rebound?

                      PetMed (PETS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        AmerisourceBergen to Take Over H. D. Smith for $815 Million

                        AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.

                          DexCom-Lily Partnership to Boost CGM Platform, Customer Base

                          DexCom (DXCM) continues to sign deals to boost CGM platform adoption.

                            Here's Why You Should Offload Fresenius Medical Stock Now

                            Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.

                              Varian to Open Facility in Brazil, Global Growth in Focus

                              Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.

                                Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind

                                Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.

                                  Sweta Killa headshot

                                  5 Cheap Dividend Growth Stocks for Thanksgiving

                                  Stuff dividend stocks with strong growth prospects in your portfolio for market-beating returns this Thanksgiving Day.

                                    Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View

                                    Medtronic (MDT) rides high on strength in major business segments in Q2.

                                      Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View

                                      Patterson Companies (PDCO) missed estimates for both the counts in Q2. A downbeat guidance indicates looming concerns.

                                        Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG

                                        Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.

                                          DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                                          DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.

                                            McKesson Gains From Distribution Business Amid Pricing Woes

                                            McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.

                                              Haemonetics (HAE) at 52-Week High: What's Driving the Stock?

                                              Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.

                                                Varian's Halcyon Receives Shonin Approval, Grows in Oncology

                                                Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.

                                                  AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                                  AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.